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MEETING REPORT
High-dose therapy: the Third UCH Meeting
R. Chopra
Department ofHaematology, University College London Medical School, London, UK.
The Third UCH High-Dose Meeting was held at University
College London in June 1993, in order to review the recent
advances and role of high-dose therapy in a variety of malig-
nant disorders. There were 175 participants and a distin-
guished cast of speakers from Europe and USA.
Historically allogeneic (allo-BMT) and then autologous
bone marrow transplantation (ABMT) have been the cor-
nerstone of high-dose therapy, mostly used to treat patients
with leukaemia and resistant and relapsed patients with lym-
phoma. The encouraging results achieved with these
treatments have led to their application in other tumours, in
particular multiple myeloma, germ cell tumours and breast
cancer. Coincident with this increase in the use of high-dose
chemotherapy and radiotherapy, there have been advances in
biotechnology with the introduction of haemopoietic growth
factors and peripheral blood stem cell support. There is now
a greater understanding of the histocompatibility system, and
the establishment of volunteer bone marrow donor registries
has made matched unrelated or volunteer unrelated donor
transplants (VUD) an increasingly practical possibility. The
aim of the UCH meeting was to review the recent advances
and to critically evaluate what impact they make on high-
dose therapy. The main themes of the meeting were:
1. the role of high-dose therapy for specific malignancies, in
particular breast cancer, multiple myeloma, acute leukaemia
and lymphoma;
2. the role of haematopoietic growth factors and peripheral
blood stem cell transplantation in high-dose therapy;
3. the role for VUD transplants in childhood leukaemia
and chronic myeloid leukaemia (CML) in adults;
4. alternative strategies for the treatment of CML.
Role ofhigh-dose therapy
Although in vitro and animal models have demonstrated a
definite and sometimes steep dose-response curve for high-
dose chemo/radiotherapy, the clinical evidence for its efficacy
is less clear-cut. Initial trials regarding high-dose therapy
have involved uncontrolled phase II studies. These studies
have enabled drug combinations and toxicity profiles to be
identified. They have also allowed the identification ofcertain
categories of patients who may benefit from further dose
escalation, but confirmation of these phase II studies through
randomised trials is necessary.
Acute myeloid leukaemia
The area in which there is probably the greatest experience to
high-dose therapy is in acute leukaemias, and Alan Burnett
from Cardiff reviewed its role in acute myeloid leukaemia
(AML). The main issue in AML is whether additional high-
dose therapy with allogeneic or autologous bone marrow
transplantation offers an advantage over consolidation con-
ventional chemotherapy once complete remission is achieved
with induction therapy. Single-centre studies and registry
data suggest that 40-55% of patients who receive allogeneic
or autologous bone marrow transplantation will enjoy pro-
longed remissions. The results of autologous BMT appear to
be equivalent to those of all allogeneic BMT and superior to
intensive chemotherapy regimens without transplant. These
studies have been criticised because of patient selection biases
and 'time censoring'. Approximately 10% of patients in com-
plete remission will relapse within 3 months and therefore
will be censored out of transplant trials. In most transplant
series the time lapse between achievement of remission and
the actual transplant procedure is approximately 3 months,
and therefore this 'time censoring' selectively favours the
transplant group. Three prospective randomised trials pub-
lished so far for AML in first remission have assessed the
role of allogeneic transplantation. Two have reported a
statistically significant advantage for patients receiving
allogeneic bone marrow transplantation (Appelbaum et al.,
1988; Zander et al., 1988) and the other study suggested that
the approaches are equivalent (Champlin et al., 1985).
Criticisms of these trials include the assertion that the doses
of chemotherapy in the non-transplant arm are not com-
parable to the newer more intensive consolidation regimens
(e.g. high-dose cytosine arabinoside). There are three ongoing
studies comparing allo-BMT, ABMT and intensive con-
solidation chemotherapy. These are the Dutch Hovon study
(Lowenberg et al., 1990), the EORTC/GIMEMA trial (Zit-
toun et al., 1990) and the UK MRC AML 10 trial. The
Dutch study suggests that allogeneic BMT results in fewer
relapses than ABMT but that the event-free survival is not
statistically different, since the allo-BMT group had a greater
procedure-related mortality. The interim analysis of the
EORTC/GIMEMA group also shows a greater mortality
rate of allo-BMT. The MRC AML 10 trial has accrued 1,400
patients from more than 100 centres in the UK, Ireland and
New Zealand. Patients under the age of 55 receive four
courses of intensive chemotherapy prior to transplantation.
The evaluation of transplantation (allogeneic or autologous)
will be its potential additional value compared with no fur-
ther chemotherapy for the non-transplant group. It is far too
early to assess what advantage if any high-dose therapy has,
but it was pointed out that approximately 180 patients
elected to stop further treatment and were not randomised.
This situation has been mirrored in the Dutch and
GIMEMA studies, highlighting the fact that even prospective
trials can lead to selection biases. Eventually a meta-analysis
of all the prospective trials may be required in order to give a
clearer indication of the benefits of high-dose therapy.
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Multiple myeloma
Diana Sampson from Charing Cross Hospital reviewed the
role of high-dose therapy in multiple myeloma. The standard
therapy for multiple myeloma has been oral melphalan and
prednisone, which produces an objective response in 50-60%
of patients and a median survival of 2.5 years. Combination
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chemotherapy such as VBMCP or ABCM, although resulting
in an improved initial CR rate, nonetheless gives the same
median survival. Moreover, there are no cures. Allo-BMT
may result in improved survival but is associated with a high
early mortality rate - mostly from infection and graft vs host
disease (Garhton et al., 1991). Furthermore, allo-BMT in
myeloma is only a viable option in those with a suitable
donor and younger patients (<50 years) with a satisfactory
performance status. This represents less than 10% of patients
with the disease. ABMT is applicable for a larger group of
patients, up to 65 years of age, but the long-term survival is
similar to conventional chemotherapy. The main problems
associated with autologous bone marrow transplantation are
an increased relapse rate, marrow contamination and lack of
a putative graft vs myeloma effect. The role ofa-interferon in
multiple myeloma for primary therapy still remains to be
clarified, with the Italian study (Mandelli et al., 1990) show-
ing a survival advantage for patients receiving a-interferon
after VAD therapy and the Scandanavian study (Osterborg
et al., 1993) showing no survival advantage. Adjuvant a-
interferon appears to prolong the plateau phase after ABMT
in the Royal Marsden study, and with a follow-up of 24
months gives a survival advantage of 12 months in the
a-interferon arm. Longer follow-up is obviously required for
this important group of patients, to ascertain whether
adjuvant treatment with a-interferon leads to durable remis-
sions or even 'cure'.
Breast cancer
Breast cancer is a major cause ofmorbidity and mortality in
young women. Although localised early disease may be cured
by local treatment such as surgery with or without radio-
therapy, there is evidence that breast cancer is a disease in
which there is early tumour dissemination. Under these cir-
cumstances chemotherapy may be beneficial. Indeed adjuvant
chemotherapy together with hormonal manipulation does
prolong survival. However, is high-dose therapy of any
benefit and when should it be used? Bill Peters presented the
experience from Duke University. Initially high-dose
chemotherapy (cyclophosphamide, cisplatin and carmustine)
was used in poor-prognosis relapsed patients with metastatic
disease. There was a high frequency of response, but these
responses were not durable, with patients relapsing at sites of
previous bulk disease. Subsequently patients received an
anthracycline-based regimen, AFM (doxorubicin, 5-fluor-
ouracil and methotrexate), to achieve cytoreduction. Those
with a complete remission and partial response proceeded to
high-dose chemotherapy and ABMT. There was an 18%
toxic death rate with significant pulmonary toxicity. However
20% of these poor-prognosis patients are alive and disease
free at 5 years. Although these data are highly promising and
suggest that dose escalation may be beneficial in breast
cancer, it was emphasised that randomised trials are needed.
The Cancer and Leukemia Group B (CALGB) are carrying
out such trials in two situations: for relapsed patients with
stage 4 metastatic disease and for patients with primary
disease with ten or more involved axillary lymph nodes.
The role ofhaemopoietic growth factors and peripheral blood
stem cell transplantation in high-dose therapy
Peripheral blood stem cells (PBSCs) to abrogate myelosupp-
ression after high-dose chemotherapy are now being used
increasingly, and the state of the art was summarised by Josy
Reiffers (Bordeaux). He reviewed the biology of peripheral
blood stem cells, highlighting the fact that peripheral blood
contains pluripotent stem cells [CD34 + ve; rhodamine dull;
quiescent (resistant to 5-FU and cytosine arabinoside); re-
spond to combinations of cytokines such as IL-1, IL-3 and
stem cell factor; and possess self-renewal capacity]. The main
advantage of the use of peripheral stem cells in transplanta-
tion is the rapid return of both neutrophil 'and platelet
populations after high-dose chemotherapy. This is only seen
when the patient receives priming with either chemotherapy,
haemopoietic growth factors or a combination of the two.
The optimal priming has yet to be evaluated. The data
suggest that a combination of granulocyte-macrophage
colony-stimulating factors (GM-CSF) and chemotherapy
such as high-dose cyclophosphamide (7 g m-2) yields the
most peripheral blood progenitors. Peripheral stem cells
could permit engraftment after most high-dose regimens in-
cluding total body irradiation and busulphan/cyclophos-
phamide, but whether long-term engraftment will be sus-
tained over a period of years remains to be seen. Patients
who have received peripheral blood stem transplants for
acute leukaemia had a delayed platelet recovery, whereas
those with lymphoma and multiple myeloma had rapid
engraftment.
Other potential advantages for PBSC transplants include
fewer infections and a reduced procedure-related mortality.
Initial data suggest that infections and antibiotic usage may
be decreased, but the impact on procedure-related mortality
remains unproven. Although most patients have a shorter
duration ofhospital stay due to neutropenia, the cost benefits
of chemotherapy and haemopoietic growth factor-primed
PBSC transplants should be evaluated by taking into account
time spent in hospital for the chemotherapy and
haemopoietic growth factor administration, and the resources
required for stem cell collections, particularly if multiple
aphereses are performed. David Linch (London) presented
the Univerity College Hospital experience of the use of
1.5 g m-2 cyclophosphamide and 5-10jig kg-' G-CSF used
to prime 18 patients with relapsed and resistant malignant
lymphomas. The patients then received BEAM (BCNU,
etoposide, cytosine arabinoside and melphalan) chemo-
therapy and could be rescued with PBSCS from a single
apheresis. The priming chemotherapy and haemopoietic
growth factor were administered on an outpatient basis with-
out any associated morbidity. The optimal time for PBSC
collection was consistently at day 9 or 10 after the cyclophos-
phamide. Marrow recovery for both neutrophils and platelets
was shortened by 7 and 11 days respectively as compared
with BEAM and ABMT. G-CSF administered after PBSC
infusion did not have a major impact on engraftment.
A major issue is whether PBSCs are preferable to bone
marrow-derived stem cells from the perspective of disease
eradication. There is no clear evidence that PBSC transplants
have a lower disease contamination, the progression-free sur-
vival of patients reported to the EBMT lymphoma registry
receiving peripheral blood stem cells being no different from
those receiving autologous marrow (Liberti et al., 1993). Jim
Armitage (Omaha), however, presented an interesting albeit
retrospective analysis of the data from Nebraska for patients
with NHL who had undergone high-dose therapy with either
ABMT or a PBSC transplant. The patients in the PBSC
group had a significantly improved progression-free survival
even though they had poorer prognostic features. This result
requires confirmation in a randomised trial.
The use of PBSCs may permit the safer use of high-dose
therapy, at least from the point of view of haematological
toxicity. However, what is the precise role of high-dose
therapy? In Hodgkin's disease there is some evidence that
high-dose therapy may lead to long-term survival in resistant
and refractory patients. This has been confirmed in a small
randomised trial (Linch et al., 1993). There are nonetheless a
group of poor-prognosis relapsed and refractory patients
who may benefit from further dose escalation. However, this
will invariably lead to non-haematological toxicity: e.g. high-
dose BCNU causing pneumonitis, and etoposide causing
mucositis and GI haemorrhage. This will not be ameliorated
by existing growth factors or PBSC transplants. In non-
Hodgkin's lymphoma, the role of high-dose chemotherapy is
generally accepted for patients with relapsed but chemosen-
sitive disease, although confirmation is awaited from ongoing
randomised trials. Indeed, in the lymphoma field, despite the
large number of high-dose procedures carried out, there have
been few randomised trials supporting this therapy. This is in
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USA, where large numbers of patients have been randomised
between 'conventional therapy' and high-dose therapy with
ABMT/PBSCs.
Volunteer unrelated donor transplantation
Jacqui Cornish from Bristol Children's Hospital presented
preliminary data on their experience of volunteer unrelated
donor (VUD) transplants. Forty-seven children (age 3
months to 17 years) received either a fully matched (28
patients) or a mismatched marrow (19 patients), the majority
with relapsed acute leukaemia. Graft vs host disease (GVHD)
prophylaxis consisted of T-cell depletion and cyclosporin A.
Four patients did not engraft. The prevalence of severe graft
vs host disease was 16% for the fully matched group and
23% for the mismatched group. The main cause of death was
not procedure related but relapse. There was no statistically
significant difference in relapse rate between the matched and
the mismatched group. The follow-up in these patients is too
short to make a meaningful assessment of long-term out-
come. It would appear that in children the incidence of graft
vs host disease is lower than in adults, as is the procedure-
related toxicity. Furthermore, one locus HLA mismatch may
not be a contraindication to its use as donor marrow in
children. In contrast, John Goldman (London) highlighted
the problems of VUD transplants in adults with chronic
myeloid leukaemia, for which there is now an increasing
number of data (Kernan et al., 1993). Unrelated donor trans-
plants are associated with a higher incidence of engraftment
problems, an increased incidence of acute and chronic
GVHD, an increase in infections and poorer overall survival
then sibling donor transplants. Furthermore, there appears to
be no difference in the relapse rate, suggesting that there is as
yet no proven additional graft vs leukaemia effect for
unrelated donor transplants. The increased incidence of
GVHD in matched unrelated patients is further evidence that
conventional serology for class I and class II HLA antigens,
together with mixed lymphocyte cultures (MLCs), is not
sensitive enough in detecting donor/recipient disparities.
Newer methods such as analysis of restriction length
polymorphisms, allospecific oligonucleotide typing, cytotoxic
T-cell precursor and helper T-cell precursor assays may be
better at predicting GVHD, thus enabling a clearer assess-
ment of outcome. VUD transplants therefore remain an ex-
perimental approach and in CML, at least, alternatives such
as autologous bone marrow transplantation should be ex-
plored.
Alternative therapies for chronic myeloid leukaemia
Alternative therapies for CGL were summarised by John
Goldman and these include the use of a-interferon and high-
dose hydroxyurea and allogeneic, volunteer donor unrelated
and autologous transplants.
The use of autologous bone marrow transplantation is
based on the premise that normal (Philadelphia chromosome
negative; bcr/abl negative) early progenitors or stem cells
persist in the marrow of CML patients. There have been
attempts to select out these normal progenitors. These in-
clude increasing Ph-negative cells in long-term bone marrow
cultures, using the loss of stromal adhesion properties in
CML to select adherent 'normal' cells, and the use of CD34+
DR- or CD 34+/Epo receptor' cells to restore normal
haemopoiesis. These in vitro manipulations are by their very
nature painstaking, and an alternative in vivo approach to
selecting Ph-negative cells was presented by Angelo Carella
(Genoa). The Genoa group have selected 66 patients with
CML (refractory to 6 months of initial a-interferon therapy
and under the age of 60 years) for treatment with myelo-
ablative idarubicin, cytosine arabinoside and etoposide. On
early recovery from the aplastic phase patients underwent
leucapheresis, the premise being that a greater proportion of
the progenitors at this stage will be Ph negative. Ten of these
patients received total body irradiation and were rescued
with the peripheral stem cells. There was prolonged marrow
recovery and median time to 0.1 x 1091`l neutrophils and
50 x 109 1' platelets was 18 and 54 days respectively. Two
patients died from aplasia. However, five out of eight
evaluable patients are Ph negative, which is undoubtedly an
impressive result, although conceptually difficult to reconcile
with the belief that in CML there is a premature release of
Ph-positive progenitor cells from the bone marrow secondary
to the abnormal loss of adhesion to the stroma (Dunbar &
Stewart, 1992).
Future trends
The meeting highlighted the fact that the use of high-dose
therapy is evolving rapidly. Conventional consolidation
therapies that do not require stem cell support are being
introduced. The choice of techniques for stem cell support is
increasing. Initially only allogeneic and subsequently
autologous bone marrow-derived stem cells were used.
Increasingly peripheral blood stem cells (both autologous and
allogeneic) will be used. There is no doubt that these allow
more rapid engraftment than marrow-derived progenitors,
but in the case of allogeneic peripheral stem cells there may
be a greater risk of GVHD since T cells will also be
mobilised. Both bone marrow-derived and peripheral blood
stem cells have now been used to purify CD34+ progenitor
cells using monoclonal antibodies. This has the theoretical
advantage of reducing contamination with tumour cells and
would be of potential benefit when there is overt bone mar-
row involvement with disease. The monoclonal antibodies
may be biotinylated as in the CellPro system (Berenson et al.,
1991). Marrow is then incubated with the antibody and
passed down a column of beads which are coated with
avidin. The biotin binds to the avidin, resulting in the pro-
genitor cells remaining behind in the column. After the
remaining marrow cells have passed through the column the
progenitors are removed by agitation. Although initial results
with this technique are encouraging from the point of view of
engraftment, whether it makes an impact on disease-free
survival remains to be proven.
Ex vivo expansion of PBSCs using a cocktail of
haemopoietic growth factors has been advocated in situations
in which limited numbers of stem cells are available, for
example because of heavy pretreatment with alkylating
agents. The problem with this approach is that ex vivo expan-
sion also results in cell differentiation, so that although there
may be initial engraftment it may not be sustained as a result
of the loss of primitive stem cells.
The technology required to deliver high-dose therapy safely
is now being optimised; the central issue as to whether
high-dose therapy cures more patients will need to be ans-
wered in some of the large-scale trials that are under way and
will be reported at the next UCH high-dose meeting.
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